<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01821989</url>
  </required_header>
  <id_info>
    <org_study_id>moos80</org_study_id>
    <nct_id>NCT01821989</nct_id>
  </id_info>
  <brief_title>Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate</brief_title>
  <official_title>Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mooselmokadem</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mooselmokadem</source>
  <brief_summary>
    <textblock>
      Hypothesis:&#xD;
&#xD;
      Orally ingested lactoferrin has effects on promotion of growth and differentiation of the&#xD;
      immature gut; also it has immunomodulatory properties, so it will prevent serious infections&#xD;
      in preterm infants.&#xD;
&#xD;
      The aim of the study is to:&#xD;
&#xD;
        -  Evaluate the effectiveness of oral lactoferrin in prevention of neonatal sepsis.&#xD;
&#xD;
        -  Compare two dose regiment of lactoferrin supplementation.&#xD;
&#xD;
        -  Study effect of lactoferrin supplementation on serum iron stores.&#xD;
&#xD;
      It is a prospective, randomized, double blind, placebo-controlled study, it will include 180&#xD;
      preterm neonates admitted to the Neonatal Intensive Care Units of of Ain Shams University&#xD;
      Hospitals and Manshiet El Bakry Hospital.&#xD;
&#xD;
      •Group A: Who will receive oral lactoferrin supplementation in a dose of 100 mg/day.&#xD;
&#xD;
      •Group B: Who will receive oral lactoferrin supplementation in a dose of 150 mg/kg/ twice&#xD;
      daily.&#xD;
&#xD;
      •Group C (Controls): Who match the subjected neonates, will receive placebo in form of&#xD;
      distilled water.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood culture</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete blood count with differential leucocytic count.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>C reactive protein quantitative assay</measure>
    <time_frame>2 years</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Neonatal Sepsis</condition>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lactoferrin,dose of 100 mg/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactoferrin, dose of 150 mg/kg/ twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receive placebo in form of distilled water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactoferrin</intervention_name>
    <description>dose of 100 mg/day</description>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactoferrin</intervention_name>
    <description>dose of 150 mg/kg/ twice daily</description>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>in form of distilled water</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Neonates with a birth weight between 500g and 2500g.&#xD;
&#xD;
          2. Neonates with a ≤ 36 weeks of gestation counting from the first day of the Last&#xD;
             Menstrual Period.&#xD;
&#xD;
          3. Preterm neonates born in, or referred to the Neonatal Intensive Care Units of one of&#xD;
             the participating hospitals in the first 48 hours of life.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Neonates with underlying gastrointestinal problems that prevent oral intake.&#xD;
&#xD;
          2. Neonates with predisposing conditions that profoundly affect growth and development&#xD;
             (chromosomal abnormalities, structural brain anomalies, severe congenital&#xD;
             abnormalities).&#xD;
&#xD;
          3. Neonates with a family background of cow milk allergy.&#xD;
&#xD;
          4. Neonates who will not have the chance to complete the study time (who will be referred&#xD;
             to another hospitals).&#xD;
&#xD;
          5. Neonates whose parents decline to participate.&#xD;
&#xD;
          6. Neonates with early onset sepsis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mostafa AM Elmokadem, Master</last_name>
    <phone>01110857100</phone>
    <phone_ext>02</phone_ext>
    <email>drmooselmokadem@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Abassia</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>March 27, 2013</study_first_submitted>
  <study_first_submitted_qc>March 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2013</study_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mooselmokadem</investigator_affiliation>
    <investigator_full_name>Mostafa El-Mokadem</investigator_full_name>
    <investigator_title>neonatologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lactoferrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

